Abstract: The infection mechanism of novel coronavirus infection involves a two-step process where the spike glycoprotein first binds to a cell surface receptor and is subsequently cleaved by a cellular protease to facilitate membrane fusion.Proton pump inhibitors (PPIs) can inhibit the spread of novel coronarirus in many ways.It inhibits cavitation proton pump to lead to raised organelle pH sorts and transports complex by targeting endosome inhibits membrane fusion and replication of novel coronavirus infection,and prevents viral transmission from infected to uninfected cells.They also can act against novel coronavirus infection by exerting anti-inflammatory and antifibrotic effects so as to reduce the clinical symptoms of pneumonia.Combined drug therapy can also be used to enhance the antiviral properties of other drugs.But the current clinical evidences do not point towards a beneficial effect clearly yet.This paper reviewed the potential therapeutic effects and clinical risks of PPIs on Coronavirus Disease 2019(COVID-19) based on the existing evidences,aiming to make clinical attention to the balance between the risks and benefiting associated with COVID-19 and PPIs.